Providers

AI-guided breast screening is advancing faster than coverage policy, guidelines, and imaging capacity—raising questions about who qualifies and who pays.

GLP-1 use in adolescents and young adults with obesity rose to 96.1% as bariatric surgery fell by two-thirds, new JAMA Pediatrics data show.

Case series suggests glofitamab bridges relapsed mantle cell lymphoma to CAR T, with strong responses and mostly low-grade CRS.

New data suggest epcoritamab plus R2 may win insurer coverage, delivering major QALY gains at approximately $68,000 and delaying costly progression.

US drug shortages rose to 227 in Q2 2026, led by a severe ifosfamide shortage.

This study examines how key players in managed care drive postacute home health referrals, identifying tensions, limited patient involvement, and barriers to care coordination.

SNAP participation was linked to a smaller colorectal cancer screening gap among food-insecure US adults, ananalysis of 251,000 found.

Alexander Spira, MD, PhD, FACP, FASCO, explains why sarcoma treatment lags behind other solid tumors and the access, subtype, and biomarker barriers.

6 leading AI chatbots scored below 28% on a colorectal cancer knowledge test when barred from reasoning, raising fresh safety concerns for clinical use.

Pharmacy eases lung cancer costs; pediatric cancer erases 40% income; BTKis widen CLL access; hospitals lag on translated aid; MN mandate ends NGS denials.

The first half of 2026 saw the FDA approve 5 notable first-in-class therapies across obesity, AML, kidney disease, hearing loss, and bladder cancer.

Quest Diagnostics is integrating its Haystack MRD and genomic profiling tests into Flatiron's OncoEMR, starting with an AON community oncology pilot.

A proposed 2027 CMS rule would cut 340B Drug Pricing Program payments to curb Medicare drug costs and shift savings to patients.

emtelligent turns unstructured data into coded clinical insights, powering payer and oncology workflows to improve trial screening, EHR-to-EDC transfer, and decisions.

At ESMO GI, Merck’s next-generation KRAS-inhibitor calderasib plus EGFR-targeting cetuximab and chemotherapy produce remarkable progression-free survival results for patients with previously untreated colorectal cancer.

OLC's second complete response letter reflects an unresolved third-party manufacturing inspection, not new efficacy or safety concerns from the FDA.

Real-world data reveal racial disparities in cancer pain medication timing and strong opioid prescribing, with gaps most pronounced in breast and prostate cancer.

Community Oncology Alliance AI Playbook powers digital health practice transformation, guiding teams to choose AI partners, protect data, and expand efficient care.

As SYMPATICO publishes final data for ibrutinib–venetoclax relapsed mantle cell lymphoma, a new commentary discusses how combinations with zanubrutinib and sonrotoclax-era could take over.

Summary of Nonconsensus Discussions: Bridging the Gaps in Health Equity & Access in Multiple Myeloma | May 2, 2026, Tampa, Florida

Caregivers of patients with CKD report social withdrawal, strained relationships, and stigma, according to a new qualitative evidence synthesis.

Those with class III obesity showed 7%+ weight loss with high engagement; Stephanie Kim, MD, MPH, talks GLP-1 complementarity and prospective study needs.

Clinicians and pharmacists at Temple and Penn discuss barriers to multidisciplinary obesity care, from ICD-10 coding gaps to prior authorization burdens.

ASCO real-world oncology data show racial disparities in pain management, with delayed meds and fewer strong opioids for Black and Asian patients.

FDA approves palbociclib (Ibrance) for HR+, HER2+ metastatic breast cancer maintenance, based on phase 3 PATINA data showing a 24% reduction in progression risk.